Calix to Participate in Barrington Research 2021 Virtual Spring Investment Conference
SAN JOSE, Calif.–(BUSINESS WIRE)–Calix, Inc. (NYSE: CALX) today announced that Calix management will participate in…
5 years ago
Website Hosting Review
First Trust Energy Infrastructure Fund Declares Its Monthly Common Share Distribution of $0.0625 Per Share for June
WHEATON, Ill.–(BUSINESS WIRE)–First Trust Energy Infrastructure Fund (the “Fund”) (NYSE: FIF) has declared the Fund’s…
5 years ago
Americold Realty Trust Declares Second Quarter 2021 Dividend
ATLANTA–(BUSINESS WIRE)–Americold Realty Trust (NYSE: COLD) (the “Company” or “Americold”), the world’s largest publicly traded…
5 years ago
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
Study leveraging the IBM® MarketScan® claims database examined healthcare resource utilization including total healthcare costs…
5 years ago
Keysight Technologies Announces New Board Member
Appoints Michelle J. Holthaus as a director effective immediately SANTA ROSA, Calif.–(BUSINESS WIRE)–$KEYS #BoardofDirectors–Keysight Technologies,…
5 years ago
Network Data Systems Prioritizes Information Security and Data Privacy Achieving ISO/IEC 27001:2013 Recertification and ISO/IEC 27701:2019 Certification
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Network Data Systems (NDS) received their 3-year recertification of ISO/IEC 27001:2013 and also…
5 years ago
Frontdoor to Participate in the J.P. Morgan 49th Annual Global Technology, Media and Communications Conference
MEMPHIS, Tenn.–(BUSINESS WIRE)–Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, today…
5 years ago
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
– Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX®) Combination –…
5 years ago
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
– Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS…
5 years ago
Braintrace Named in 2021 Gartner ‘Emerging Technologies: Adoption Growth Insights for Network Detection and Response’ Report
Dragonfly, Braintrace’s Proprietary Network Detection and Response (NDR) Application, Is Recognized for Its Early Malware…
5 years ago